

## **EXHIBIT U**

611

1                 UNITED STATES DISTRICT COURT  
2                 FOR THE DISTRICT OF MASSACHUSETTS  
3                 -----X MDL NO. 1456  
4         IN RE: PHARMACEUTICAL INDUSTRY : CIVIL ACTION:  
5         AVERAGE WHOLESALE PRICE LITIGATION : 01-CV-12257-PBS  
6                 -----X  
7         THIS DOCUMENT RELATES TO: :  
8         U.S. ex rel. Ven-A-Care of the : CIVIL ACTION:  
9         Florida Keys, Inc. v. Abbott : 06-CV-11337-PBS  
10         Laboratories, Inc. :  
11                 -----X  
12         IN THE CIRCUIT COURT OF  
13         MONTGOMERY COUNTY, ALABAMA  
14                 -----X  
15         STATE OF ALABAMA, : CASE NO.  
16         Plaintiff, : CV-05-219  
17         v. :  
18         ABBOTT LABORATORIES, INC., : JUDGE  
19         et al., : CHARLES PRICE  
20         Defendants. :  
21                 -----X  
22         Deposition of DAVID TAWES, Volume III

1 there wasn't an F drive.

2 Q. And do you know what the source was of  
3 the catalog information that was compiled for the  
4 1997 report that's been labeled Abbott Exhibit 002?

5 MR. WINGET-HERNANDEZ: Objection, form.

6 THE WITNESS: We received drug pricing  
7 catalogs from Ven-A-Care.

8 BY MR. GORTNER:

9 Q. Do you know if the entire report was  
10 based upon information that you received from  
11 Ven-A-Care?

12 A. I don't know.

13 Q. Do you have any reason to believe that  
14 the prices that are documented in Roxane Exhibit  
15 013 and Roxane Exhibit 014 were not received from  
16 Ven-A-Care?

17 A. No.

18 Q. I'm going to hand you what's been  
19 previously marked as Roxane Exhibit 002. This  
20 particular version will not have the designation of  
21 Roxane Exhibit 002, but it, in fact, was marked as  
22 Roxane Exhibit 002. And I prefer not to mark

1 identical copies with different exhibit numbers.

2 For the record, this is a document  
3 Bates labeled HHD009-0977 through 0981.

4 At the top of the document, there is  
5 a title that states: Excessive Medicare  
6 reimbursement for prescription drugs and has a  
7 paren with the actual number of the report, and  
8 then it says: Information compiled from Ven-A-Care  
9 exhibits.

10 Could you flip through this document  
11 quickly, Mr. Tawes, and let me know whether you  
12 recognize it?

13 A. No, I do not recognize it.

14 Q. This isn't a document that you worked on?

15 A. No.

16 Q. But this was a document that was located  
17 in the working files of this 1997 report? I will  
18 represent to you that that's what we were informed.

19 A. Okay.

20 Q. The document appears to contain a variety  
21 of pricing information on several drugs. I would  
22 ask you to kind of look over the drugs on this

1 document, and let me know if they correspond with  
2 the drugs that were, in fact, reported on in the  
3 December 1997 Office of Inspector General report.

4 A. Yes, they are.

5 Q. In particular, I would like you to turn  
6 to Page 4 of this document that's Bates labeled  
7 HHD009-0980.

8 A. (Witness complies.)

9 Q. Do you see that there is a listing there  
10 for Ipratropium Bromide?

11 A. Yes.

12 Q. Do you see that? And it appears to list  
13 three different NDCs.

14 Do you see that?

15 A. Yes. Actually, it is three of the same  
16 NDCs.

17 Q. I'm sorry, you are correct, three NDCs.  
18 But under the column entitled Ven-A-Care, do you  
19 see that there are three entries on the row? One  
20 row reads PC, one row reads IV med, and one reads  
21 HSCA, do you see that?

22 A. Yes.

1 Q. And do you have any idea what that stands  
2 for?

3 A. It would look like that it is the  
4 catalogs or the pricing source.

5 Q. And would you characterize those as three  
6 different pricing sources?

7 A. I can't say for sure whether any of those  
8 are related or not.

9 Q. And then you can see that if you follow  
10 the rows off further to the right, there is a  
11 column that reads NDC, and there are three prices  
12 there. Do you see that, \$31.13?

13 A. Yes.

14 Q. Would that suggest to you that here, the  
15 Office of Inspector General, in fact, had compiled  
16 the pricing on Ipratropium Bromide for these NDCs  
17 from Ven-A-Care?

18 A. Yes.

19 Q. Do you know whether the Office of  
20 Inspector General, in its normal course of duties,  
21 prepares sheets like this that compile information  
22 that they receive on drug prices?

1 testified to this before, that you have not done a  
2 study of utilization of particular drugs as a  
3 function of AWP prices, have you?

4 A. No.

5 Q. And is it correct to say that you have  
6 never worked in a pharmacy?

7 A. No. Sorry. I have not worked in a  
8 pharmacy.

9 Q. I twisted that one up on you a little  
10 bit.

11 Would it also be correct to say that  
12 you, as part of your responsibilities for the OIG,  
13 you have never done a study to determine how  
14 pharmacies actually acquire the drugs that they  
15 dispense?

16 A. Correct.

17 Q. Now, there has been a lot of testimony  
18 and conversation about Ven-A-Care -- I will try and  
19 say it right -- Ven-A-Care of the Florida Keys. And  
20 I don't want to go through all of that again, but  
21 it is correct to say that Ven-A-Care provided  
22 pricing information for a number of the reports

1       that we have looked at; correct?

2           A.    Either provided the pricing information  
3       or provided us access to get the pricing  
4       information.

5           Q.    And when you say provided the pricing  
6       information, you are talking about the catalogs  
7       that Ven-A-Care provided; correct?

8           A.    Yes.

9           Q.    Did they provide catalogs on just one  
10      occasion that you are aware of or was it multiple  
11      occasions?

12          A.    Multiple occasions.

13          Q.    Do you know when the first time  
14      Ven-A-Care provided pricing catalogs?

15          A.    No.

16          Q.    Are they still providing pricing catalogs  
17      to you?

18          A.    No.

19          Q.    Do you still -- I understand the other  
20      source of information that they have given you is  
21      access to on-line pharmacy prices; correct?

22          A.    Yes.

1 against First Databank?

2 A. No.

3 Q. What is your understanding of how the DOJ  
4 AWPs were calculated?

5 A. They were calculated based on information  
6 provided by Ven-A-Care.

7 Q. Do you know what information -- and  
8 provided by whom -- sorry, provided by Ven-A-Care  
9 to whom?

10 A. I don't know.

11 Q. Do you know what information Ven-A-Care  
12 provided that formed the basis of the DOJ AWPs?

13 A. Catalog prices.

14 Q. Do you believe that the information that  
15 Ven-A-Care provided that form the basis of the DOJ  
16 AWPs was the same information that you utilized in  
17 publishing your reports?

18 A. I don't know.

19 Q. Did you ever have any conversations with  
20 anyone at the DOJ regarding those DOJ AWPs?

21 A. Not that I recall.

22 Q. Do you know if the DOJ AWPs were based on

1 purchasing organizations?

2 A. Not that I know of.

3 Q. Do you know whether Ven-A-Care ever  
4 provided you or your office, anyone else at OIG  
5 with pricing information from group purchasing  
6 organizations?

7 A. Yes, they did.

8 Q. And was that information otherwise not  
9 available to OIG?

10 MS. TORGERSON: Objection to form.

11 THE WITNESS: I don't believe that  
12 it would have been.

13 BY MR. AZORSKY:

14 Q. You indicated earlier that Ven-A-Care  
15 provided OIG with access to on-line wholesaler  
16 prices; is that correct?

17 A. Yes.

18 Q. And by providing access to those on-line  
19 wholesaler prices, do you mean to say that those  
20 prices were password-protected?

21 A. Yes.

22 Q. And without a password, OIG did not have

1 BY MR. AZORSKY:

2 Q. And to your knowledge, did Ven-A-Care  
3 provide McKesson's pricing sheets for prices of  
4 pharmaceuticals to pharmaceutical providers, did  
5 they provide those sheets to OIG?

6 A. Yes.

7 Q. And in fact, generally, the prices that  
8 Ven-A-Care provided to OIG to your knowledge  
9 consisted of confidential prices that were not  
10 accessible, unless it came from an industry  
11 insider; is that correct?

12 MR. GABEL: Objection.

13 MR. GORTNER: Objection, form.

14 MS. TORGERSON: Objection.

15 MS. REID: Objection.

16 THE WITNESS: Yes.

17 MR. AZORSKY: I have no further  
18 questions.

19 THE VIDEO TAPE OPERATOR: Off the  
20 video, 2:06.

21 THE VIDEO TAPE OPERATOR: Back on the  
22 video, 2:06.